Emerging effects of comorbidities on multiple sclerosis

The Lancet Neurology

Volumn 9, Issue 8, 2010, Pages 820-828

  Marrie, Ruth Ann ^a   Horwitz, Ralph I ^b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY DISORDER; BIPOLAR DISORDER; CHRONIC LUNG DISEASE; CLINICAL DECISION MAKING; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DISABILITY SEVERITY; ENTERITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IRRITABLE COLON; MULTIPLE SCLEROSIS; NARCOLEPSY; OBESITY; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; REVIEW; RHEUMATOID ARTHRITIS; SLEEP DISORDER; SMOKING; SOCIAL STATUS; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE;

COMORBIDITY; HUMANS; MULTIPLE SCLEROSIS; OBESITY; SMOKING;

EID: 77955312194     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70135-6     Document Type: Review

References (93)

1. Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA Causes and consequences of comorbidity: a review. J Clin Epidemiol 2001, 54:661-674.
2. Hoffman C, Rice D, Sung HY Persons with chronic conditions. Their prevalence and costs. JAMA 1996, 276:1473-1479.
3. Lacey CJ, Salzberg MR, Roberts H, Trauer T, D'Souza WJ Psychiatric comorbidity and impact on health service utilization in a community sample of patients with epilepsy. Epilepsia 2009, 50:1991-1994.
4. Devinsky O, Ehrenberg B, Barthlen GM, Abramson HS, Luciano D Epilepsy and sleep apnea syndrome. Neurology 1994, 44:2060-2064.
5. Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007, 69:1850-1858.
6. Dean G How many people in the world have multiple sclerosis. Neuroepidemiology 1994, 13:1-7.
7. Beck CA, Metz LM, Svenson LW, Patten SB Regional variation of multiple sclerosis prevalence in Canada. Mult Scler 2005, 11:516-519.
8. Leary SM, Porter B, Thompson AJ Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J 2005, 81:302-308.
9. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006, 13:700-722.
10. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M Defining comorbidity: implications for understanding health and health services. Ann Fam Med 2009, 7:357-363.
11. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 2006, 5:924-931.
12. Edwards LJ, Constantinescu CS A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler 2004, 10:575-581.
13. Midgard R, Gronning M, Riise T, Kvale G, Nyland H Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol Scand 1996, 93:322-328.
14. Seyfert S, Klapps P, Meisel C, Fischer T, Junghan U Multiple sclerosis and other immunologic diseases. Acta Neurol Scand 1990, 81:37-42.
15. Marrie RA Autoimmune disease and multiple sclerosis: methods, methods, methods. Lancet Neurol 2007, 6:575-576.
16. Gupta G, Gelfand JM, Lewis JD Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005, 129:819-826.
17. Bernstein CN, Wajda A, Blanchard JF The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005, 129:827-836.
18. Kimura K, Hunter S, Thollander MS, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc 2000, 75:802-806.
19. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DAS Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000, 123:1102-1111.
20. Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999, 5:369-376.
21. Niederwieser G, Buchinger W, Bonelli RM, et al. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J Neurol 2003, 250:672-675.
22. Sloka JS, Pryse-Phillips WEM, Stefanelli M, Joyce C Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J Autoimmune Dis 2005, 2:9.
23. De Keyser J Autoimmunity in multiple sclerosis. Neurology 1988, 38:371-374.
24. NARCOMS Multiple Sclerosis Registry Consortium of Multiple Sclerosis Centers, (accessed Jan 5, 2008). http://www.mscare.org/cmsc/CMSC-NARCOMS-Information.html.
25. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T Comorbidity, socioeconomic status, and multiple sclerosis. Mult Scler 2008, 14:1091-1098.
26. Prevalence of disability and associated health conditions, United States, 1991-1992. MMWR Morb Mortal Wkly Rep 1994, 40:730-731. Centers for Disease Control and Prevention, 737-39.
27. Marrie RA. The influence of comorbid diseases and health behaviors on clinical characteristics, disability at diagnosis, and disability progression in multiple sclerosis. PhD thesis, Case Western Reserve University, 2007; 1-547.
28. Warren SA, Turpin KV, Pohar SL, Jones CA, Warren KG Comorbidity and health-related quality of life in people with multiple sclerosis. Int J MS Care 2009, 11:6-16.
29. Brass SD, Duquette P, Proulx-Therrien J, Auerbach S Sleep disorders in patients with multiple sclerosis. Sleep Med Rev 2010, 14:121-129.
30. Manconi M, Ferini-Strambi L, Filippi M, et al. Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep 2008, 31:944-952. the Italian REMS Study Group.
31. Deriu M, Cossu G, Molari A, et al. Restless legs syndrome in multiple sclerosis: a case-control study. Mov Disord 2009, 24:697-701.
32. Auger C, Montplaisir J, Duquette P Increased frequency of restless legs syndrome in a French-Canadian population with multiple sclerosis. Neurology 2005, 65:1652-1653.
33. Gomez-Choco M, Iranzo A, Blanco Y, Graus F, Santamaria J, Saiz A Prevalence of restless legs syndrome and REM sleep behavior disorder in multiple sclerosis. Mult Scler 2007, 13:805-808.
34. Manconi M, Fabbrini M, Bonanni E, et al. High prevalence of restless legs syndrome in multiple sclerosis. Eur J Neurol 2007, 14:534-539.
35. Nishino S, Kanbayashi T Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005, 9:269-310.
36. Ajayi OF, Chang-McDowell T-Y, Culpepper WJ, Royal W, Bever C High prevalence of sleep disorders in Veterans with multiple sclerosis. Neurology 2008, 70(suppl 1):A333.
37. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005, 11:328-337. Goldman Consensus Group.
38. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
39. Korostil M, Feinstein A Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007, 13:67-72.
40. Poder K, Ghatavi K, Fisk J, et al. Social anxiety in a multiple sclerosis clinic population. Mult Scler 2009, 15:393-398.
41. Somers JM, Goldner EM, Waraich P, Hsu L Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 2006, 51:100-113.
42. Fisk J, Morehouse SA, Brown MG, Skedgel C, Murray TJ Hospital-based psychiatric service utilization and morbidity in multiple sclerosis. Can J Neurol Sci 1998, 25:230-235.
43. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z Mood disorder and multiple sclerosis. Arch Neurol 1987, 44:376-378.
44. Patten SB, Svenson LW, Metz LM Psychotic disorders in MS: population-based evidence of an association. Neurology 2005, 65:1123-1125.
45. Pine DS, Douglas CJ, Charles E, Davies MB, Kahn D Patients with multiple sclerosis presenting to psychiatric hospitals. J Clin Psychiatry 1995, 56:297-306.
46. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T High frequency of adverse health behaviors in multiple sclerosis. Mult Scler 2009, 15:105-113.
47. Quesnel S, Feinstein A Multiple sclerosis and alcohol: a study of problem drinking. Mult Scler 2004, 10:197-201.
48. Khurana SR, DiGiacomo AM, Rohini V, et al. Prevalence of overweight and obesity among Veterans with multiple sclerosis. Int J MS Care 2006, 8:59.
49. Marrie RA, Horwitz RI, Cutter G, Tyry T, Campagnolo D, Vollmer T Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009, 72:117-124.
50. Bjerager M, Palshof T, Dahl R, Vedsted P, Olesen F Delay in diagnosis of lung cancer in clinical practice. Br J Gen Pract 2006, 56:863-868.
51. Healy BC, Ali EN, Guttmann CRG, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009, 66:858-864.
52. Kirby S, Brown MG, Murray TJ, et al. Progression of multiple sclerosis in patients with other autoimmune diseases. Mult Scler 2005, 11(suppl 1):S28-S29.
53. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010, 74:1041-1047.
54. Dallmeijer AJ, Beckerman H, de Groot V, van de Port IG, Lankhorst GJ, Dekker J Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehabil Med 2009, 41:322-326.
55. Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H Cigarette smoking and the progression of multiple sclerosis. Brain 2005, 128:1461-1465.
56. Sundstrom P, Nystrom L Smoking worsens the prognosis in multiple sclerosis. Mult Scler 2008, 14:1031-1035.
57. Di Pauli F, Reindl M, Ehling R, et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 2008, 14:1026-1030.
58. Sena A, Couderc R, Ferret-Sena V, et al. Apolipoprotein E polymorphism interacts with cigarette smoking in progression of multiple sclerosis. Eur J Neurol 2009, 16:832-837.
59. Pittas F, Ponsonby AL, van der Mei IA, et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 2009, 256:577-585.
60. Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009, 73:504-510.
61. Hermann B, Vickrey B, Hays RD, et al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 1996, 25:113-118.
62. Wu N, Minden SL, Hoaglin DC, Hadden L, Frankel D Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm 2007, 30:233-267.
63. Turpin KV, Carroll LJ, Cassidy JD, Hader WJ Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult Scler 2007, 13:1038-1045.
64. Francis G Benefit-risk assessment of interferon-b therapy for relapsing multiple sclerosis. Expert Opin Drug Saf 2004, 3:289-303.
65. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923.
66. Bayliss EA, Steiner JF, Fernald DH, Crane LA, Main DS Descriptions of barriers to self-care by persons with comorbid chronic diseases. Ann Fam Med 2003, 1:15-21.
67. Gulick EE Emotional distress and activities of daily living functioning in persons with multiple sclerosis. Nurs Res 2001, 50:147-154.
68. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991, 114:1045-1056.
69. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
70. Launer LJ Diabetes and brain aging: epidemiologic evidence. Curr Diab Rep 2005, 5:59-63.
71. Health, United States, 2005. With chartbook on Trends in the Health of Americans 2005, 1-535. National Center for Health Statistics, US Department of Health and Human Services, Hyattsville, MD, 2005, (accessed July 28, 2010). http://www.cdc.gov/nchs/data/hus/hus05.pdf.
72. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P Smoking and lung cancer survival. The role of comorbidity and treatment. Chest 2004, 125:27-37.
73. Weil E, Wachterman M, McCarthy EP, et al. Obesity among adults with disabling conditions. JAMA 2002, 288:1265-1268.
74. Trojano M, Liguori M, Zimatore G Bosco, et al. Age-related disability in multiple sclerosis. Ann Neurol 2002, 51:475-480.
75. Tremlett H, Zhao Y, Joseph J, Devonshire V Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatr 2008, 79:1368-1374.
76. Pfleger CCH, Flachs EM, Koch-Henriksen N Social consequences of multiple sclerosis (1): early pension and temporary unemployment-a historical prospective cohort study. Mult Scler 2010, 16:121-126.
77. Pfleger CCH, Flachs EM, Koch-Henriksen N Social consequences of multiple sclerosis: clinical and demographic predictors: a historical prospective cohort study. Eur J Neurol 2010, published online April 9. 10.1111/j.1468-1331.2010.03020.x.
78. Braveman PA, Cubbin C, Egerter S, et al. Socioeconomic status in health research: one size does not fit all. JAMA 2005, 294:2879-2888.
79. Steenland K, Hu S, Walker J All-cause and cause-specific mortality by socioeconomic status among employed persons in 27 US states, 1984-1997. Am J Public Health 2004, 94:1037-1042.
80. Minkler M, Fuller-Thomson E, Guralnik JM Gradient of disability across the socioeconomic spectrum in the United States. N Engl J Med 2006, 355:695-703.
81. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D Does multiple sclerosis-associated disability differ between races?. Neurology 2006, 66:1235-1240.
82. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology 2007, 68:1971-1978.
83. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004, 57:1096-1103.
84. Bayliss EA, Ellis JL, Steiner JF Subjective assessments of comorbidity correlate with quality of life health outcomes: initial validation of a comorbidity assessment instrument. Health Qual Life Outcomes 2005, 2:51.
85. Klabunde CN, Warren JL, Legler JM Assessing comorbidity using claims data: an overview. Med Care 2002, 40(8 suppl):IV-26-IV-35.
86. Marrie RA, Yu N, Blanchard JF, Leung S, Elliott L The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010, 74:465-471.
87. Hohol MJ, Orav EJ, Weiner HL Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler 1999, 5:349-354.
88. Horton M, Rudick RA, Hara-Cleaver C, Marrie RA Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology 2010, 35:83-90.
89. Culpepper WJ, Ehrmantraut M, Wallin MT, Flannery K, Bradham DD Veterans Health Administration multiple sclerosis surveillance registry: the problem of case-finding from administrative databases. J Rehabil Res Dev 2006, 43:17-24.
90. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999, 149:916-924.
91. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003, 56:221-229.
92. Byles JE, D'Este C, Parkinson L, O'Connell R, Treloar C Single index of multimorbidity did not predict multiple outcomes. J Epidemiol 2005, 58:997-1005.
93. Grunau GL, Sheps S, Goldner EM, Ratner PA Specific comorbidity risk adjustment was a better predictor of 5-year acute myocardial infarction mortality than general methods. J Clin Epidemiol 2006, 59:274-280.